Optimizing Outcomes of Rectal Cancer in 2019 (C)
This session has been identified and designated as Credit to Meet ACS Accreditation/Verification Requirements for Cancer. Learn more about ACS Accreditation/Verification Requirements.
Management of rectal cancer is becoming increasingly challenging with growing options for local management and nonoperative management of patients after neoadjuvant chemoradiotherapy with complete clinical response. This panel will provide an update on the rapidly changing landscape of rectal cancer management.
Moderator: Steven D. Wexner, MD, PhD(Hon), FACS, FRCSEng, FRCSEd, FRCSI(Hon), FRCSGlasg(Hon), Weston, FL
Co-Moderator: Arden M. Morris, MD, MPH, FACS, Stanford, CA
Steven D. Wexner, MD, PhD(Hon), FACS, FRCSEng, FRCSEd, FRCSI(Hon), FRCSGlasg(Hon), Weston, FL
Arden M. Morris, MD, MPH, FACS, Stanford, CA
The Value of the American College of Surgeons Commission on Cancer National Accreditation Program for Rectal Cancer Accreditation
Heidi Nelson, MD, FACS, Chicago, IL
Should Adjuvant Chemotherapy Be Replaced by Neoadjuvant Therapy?
George J. Chang, MD, FACS, Houston, TX
The Rationale and Current Status of Wait and Watch after Complete Response
Julio E. Garcia-Aguilar, MD, FACS, New York, NY
How Collaboratives Improve Rectal Cancer Care
Samantha K. Hendren, MD, FACS, Ann Arbor, MI
Sponsored by the Advisory Council for Colon and Rectal Surgery and the Advisory Council for General Surgery
- Practicing surgeons
- Apply new knowledge and ideas to improve their surgical practice
- Adapt concepts and quality measures in support of research advancements
- Enhance the quality of patient care
For questions about the course, please contact firstname.lastname@example.org.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation.
(Download the full list of disclosures).
Faculty and Disclosures
Arden M. Morris MD, MPH, FACS - Nothing to Disclose
George J. Chang, MD, FACS - Johnson and Johnson: Consulting Fee: Consultant; MOREHealth: Consulting Fee: Consultant
Heidi Nelson MD, FACS - Nothing to Disclose
Julio E. Garcia-Aguilar MD, FACS - Nothing to Disclose
Samantha K. Hendren MD, FACS - Nothing to Disclose
Steven D. Wexner, MD, PhD (Hon), FACS, FRCS (Eng), FRCS(Ed), FRCSI (Hon), Hon FRCS (Glasg) - Intuitive Surgical: Royalty payments and consulting fees: Intellectual property license and consulting; Karl Storz Endoscopy: Royalty payments and consulting fees: Intellectual property license and consulting; Medtronic: Royalty payments and consulting fees: Intellectual property license and consulting; Regentys: Consulting Fee: Consultant/Chief Medical Officer; Takeda/Tigenix: Consulting Fee: Consulting
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - Nothing to Disclosure
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - Nothing to Disclosure
David C. Borgstrom, MD, FACS, Morgantown, WV - Nothing to Disclosure
Daniel L. Dent, MD, FACS, San Antonio, TX - Nothing to Disclosure
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Cynthia D. Downard, MD, FACS, Louisville, KY - Nothing to Disclosure
Audra A. Duncan, MD, FACS, London, ON - Nothing to Disclosure
Mariam F. Eskander, MD, Boston, MA - Nothing to Disclosure
Paula Ferrada, MD, FACS, Richmond, VA - Nothing to Disclosure
Neil H. Hyman, MD, FACS, Chicago, IL - Nothing to Disclosure
Martin S. Karpeh, Jr., MD, FACS, New York, NY - Nothing to Disclosure
Dennis H. Kraus, MD, FACS, New York, NY - Nothing to Disclosure
Kenneth W. Sharp, MD, FACS, Nashville, TN - Nothing to Disclosure
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - Nothing to Disclosure
Edith Tzeng, MD, FACS, Pittsburgh, PA - Nothing to Disclosure
Barbara Lee Bass, MD, FACS, FRCSEng(Hon), FRCSI(Hon), FCOSECSA(Hon), Houston, TX - Nothing to Disclosure
Quan-Yang Duh, MD, FACS, San Francisco, CA - Nothing to Disclosure
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - Nothing to Disclosure
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - Nothing to Disclosure
Note: Residents will receive a Certificate of Completion.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Certificate of Completion
- 1.50 Self Assessment Credit